Polyethylene Glycol Derivatives for Protein Therapeutic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional polyethylene glycol (PEG) compounds used in protein therapeutics have varying reactivity due to their structures, making it challenging to effectively bind to target materials, which hinders the improvement of manufacturing yields and stability of medicaments.
Innovation Solution
Development of novel polyethylene glycol derivatives with specific reactive end groups, such as aldehyde, ortho-pyridyl disulfide, and halogenated acetamide, that can easily react with physiologically active polypeptides and carrier proteins to enhance their in vivo half-life and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PEG compounds with reactive groups are used, then binding to target materials is achieved, but reactivity varies due to structural differences making manufacturing difficult
Solution Approach 1:
The patent modifies the chemical structure of PEG compounds by introducing specific reactive groups (aldehyde, ortho-pyridyl disulfide, halogenated acetamide) at defined positions, changing the chemical parameters to achieve consistent reactivity while maintaining binding reliability to target materials
Solution Approach 2:
The patent applies different reactive groups to specific locations (ends) of the PEG molecule, creating localized reactivity zones that ensure consistent interaction with target materials while the rest of the PEG structure maintains its biocompatibility and binding properties
2Stability of the object's composition
If PEGylation is performed to improve stability, then protein therapeutic stability increases, but manufacturing yield improves only with sophisticated technology
Solution Approach 1:
The patent changes the chemical parameters of PEG compounds by introducing reactive groups that facilitate easier and more efficient conjugation to proteins, thereby improving manufacturing yield while maintaining the stability-enhancing effects of PEGylation
Solution Approach 2:
The patent uses PEG compounds with reactive groups as intermediaries that bridge the protein therapeutic and the carrier protein, enabling stable conjugation while simplifying the manufacturing process and improving yield
3Adaptability or versatility
If reactive groups are added to PEG ends, then binding capability is improved, but reactivity consistency deteriorates due to structural variations
Solution Approach 1:
The patent standardizes the chemical parameters by selecting specific reactive groups (aldehyde, ortho-pyridyl disulfide, halogenated acetamide) with known and consistent reactivity characteristics, ensuring reliable binding capability across different PEG compounds while maintaining versatility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new PEG derivatives improve the reactivity and stability of protein therapeutics by easily linking to target materials, increasing the in vivo half-life of physiologically active polypeptides and facilitating the production of conjugates with enhanced manufacturing yields.
Implementation Method 1
reacting the polyethylene glycol compound with a physiologically active polypeptide to prepare a physiologically active polypeptide to which a polyethylene glycol compound is attached
Implementation Method 2
reacting the polyethylene glycol compound with a carrier protein to prepare a carrier protein to which a polyethylene glycol compound is attached
Data Source
AI summary
Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.